Ngā hua rapu

Ngā kaupapa kua whakahuatia i roto i tō rapu.
Whakamahine hua
  1. 1
    Macrolides for diffuse panbronchiolitis

    Macrolides for diffuse panbronchiolitis mā Xiufang Lin, Jing Lu, Ming Yang, Bi Rong Dong, Hong Wu

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Role of macrolide therapy in chronic obstructive pulmonary disease

    Role of macrolide therapy in chronic obstructive pulmonary disease mā Fernando J. Martínez, Jeffrey L. Curtis, Richard Albert

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis

    Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis mā Takeaki Hiratsuka

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Mimics in chest disease: interstitial opacities

    Mimics in chest disease: interstitial opacities mā Anastasia Oikonomou, Panos Prassopoulos

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    The Lung in Inflammatory Bowel Disease†

    The Lung in Inflammatory Bowel Disease† mā Philippe Camus, F Piard, T Ashcroft, Anthony A. Gal, Thomas V. Colby

    I whakaputaina 1993
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.

    Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. mā Takeshi Fujii, J Kadota, K Kawakami, Kei Iida, Ryo Shirai, M Kaseda, Sadahiro Kawamoto, S Kohno

    I whakaputaina 1995
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Fourteen-Member Macrolides Promote the Phosphatidylserine Receptor-Dependent Phagocytosis of Apoptotic Neutrophils by Alveolar Macrophages

    Fourteen-Member Macrolides Promote the Phosphatidylserine Receptor-Dependent Phagocytosis of Apoptotic Neutrophils by Alveolar Macrophages mā Takeshi Yamaryo, Kazunori Oishi, Hiroyuki Yoshimine, Yoshiko Tsuchihashi, Kouji Matsushima, Tsuyoshi Nagatake

    I whakaputaina 2002
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    The Role of Macrolides in Noncystic Fibrosis Bronchiectasis

    The Role of Macrolides in Noncystic Fibrosis Bronchiectasis mā Bruna de Campos Guimarães e Figueiredo, Cássio da Cunha Ibiapina

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy

    Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy mā Josje Altenburg, Casper S. de Graaff, Tjip S. van der Werf, Wim Boersma

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications

    Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications mā Soichiro Kanoh, Bruce K. Rubin

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Small airways diseases: detection and insights with computed tomography

    Small airways diseases: detection and insights with computed tomography mā D.M. Hansell

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration

    Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration mā Heidi Schilter, Adam Collison, Remo Castro Russo, Jonathan S. Foot, Tin T. Yow, Angélica T. Vieira, Lívia D. Tavares, Joërg Mattes, Mauro Martins Teixeira, Wolfgang Jarolimek

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappaB transcription factors

    Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappaB transcription factors mā Tohru Kikuchi

    I whakaputaina 2002
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia

    High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia mā Hiroshi Ishii

    I whakaputaina 2003
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Serum Levels of CA19‐9 in patients with nonmalignant respiratory diseases

    Serum Levels of CA19‐9 in patients with nonmalignant respiratory diseases mā Takahide Kodama, Hiroaki Satoh, Hiroichi Ishikawa, Morio Ohtsuka

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Infections Caused by Chlamydophila pneumoniae

    Infections Caused by Chlamydophila pneumoniae mā Irena Choroszy−Król, Magdalena Frej−Mądrzak, Hober Martyna, Jolanta Sarowska, Agnieszka Jama−Kmiecik

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Azithromycin Inhibits MUC5AC Production Induced by the<i>Pseudomonas aeruginosa</i>Autoinducer<i>N</i>-(3-Oxododecanoyl) Homoserine Lactone in NCI-H292 Cells

    Azithromycin Inhibits MUC5AC Production Induced by the<i>Pseudomonas aeruginosa</i>Autoinducer<i>N</i>-(3-Oxododecanoyl) Homoserine Lactone in NCI-H292 Cells mā Yoshifumi Imamura, Katsunori Yanagihara, Yohei Mizuta, Masafumi Seki, Hideaki Ohno, Yasuhito Higashiyama, Yoshitsugu Miyazaki, Kazuhiro Tsukamoto, Yoichi Hirakata, Kazunori Tomono, Jun‐ichi Kadota, Shigeru Kohno

    I whakaputaina 2004
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Erythromycin shortens neutrophil survival by accelerating apoptosis

    Erythromycin shortens neutrophil survival by accelerating apoptosis mā Kazutetsu Aoshiba, Atsushi Nagai, K. Konno

    I whakaputaina 1995
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions

    Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions mā Charles Haworth, Diana Bilton, J.S. Elborn

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Secretion properties, clearance, and therapy in airway disease

    Secretion properties, clearance, and therapy in airway disease mā Bruce K. Rubin

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: